PTX 2.44% 4.2¢ prescient therapeutics limited

Ann: PTX-200 AML Trial Progresses to Higher Dose, page-30

  1. 1,656 Posts.
    lightbulb Created with Sketch. 198
    Also, I realise the ‘chance’ factor to the equation ( the possible that the 3 participants may have been most likely to the CR ratio than others) , yet the same can be said about the next 3 participants on the escalating dose. Certainly a larger larger population study at this efficacy would make sense (to me anyway) outside the clouded reporting itself.
 
watchlist Created with Sketch. Add PTX (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.